Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Longeveron ( (LGVN) ) just unveiled an announcement.
On October 1, 2025, Longeveron Inc. announced the appointment of Dr. George Paletta to its Board of Directors. Dr. Paletta, an internationally recognized orthopedic surgeon and entrepreneur, brings extensive experience in medicine and business to the company. His appointment comes at a pivotal time for Longeveron as it advances its stem cell therapy pipeline, including a pivotal clinical trial in hypoplastic left heart syndrome with data expected in 2026. This strategic addition is expected to enhance Longeveron’s efforts in commercializing stem cell therapies, benefiting healthcare, patients, and shareholders.
The most recent analyst rating on (LGVN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.
Spark’s Take on LGVN Stock
According to Spark, TipRanks’ AI Analyst, LGVN is a Neutral.
Longeveron’s overall stock score is primarily impacted by its financial performance, which shows significant challenges with declining revenues and persistent losses. Technical analysis further indicates bearish momentum. While the earnings call highlighted strategic progress, financial uncertainties and increased expenses weigh heavily on the score.
To see Spark’s full report on LGVN stock, click here.
More about Longeveron
Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs. Its lead investigational product, laromestrocel (Lomecel-B™), is an allogeneic mesenchymal stem cell therapy with potential applications in various disease areas, including hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty. The company has received multiple FDA designations for its development programs.
Average Trading Volume: 1,033,944
Technical Sentiment Signal: Sell
Current Market Cap: $16.22M
See more data about LGVN stock on TipRanks’ Stock Analysis page.